Premium
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen
Author(s) -
Booth Christopher M.,
Pater Joseph L.,
Goss Paul E.
Publication year - 2007
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22613
Subject(s) - medicine , tamoxifen , breast cancer , letrozole , aromatase inhibitor , adjuvant therapy , anastrozole , population , absolute risk reduction , hormonal therapy , gynecology , cancer , oncology , confidence interval , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom